Journal
JOURNAL OF BIOCHEMISTRY
Volume 153, Issue 3, Pages 243-249Publisher
OXFORD UNIV PRESS
DOI: 10.1093/jb/mvs152
Keywords
angiogenesis; anti-angiogenic therapy; drug resistance; endothelial cells; tumours
Categories
Funding
- Ministry of Education, Science, and Culture of Japan [21659458, 23390457]
- Akiyama Foundation
- Grants-in-Aid for Scientific Research [23890009, 21659458, 24791958, 23390457, 24890007] Funding Source: KAKEN
Ask authors/readers for more resources
Tumour growth is dependent on angiogenesis, and tumour blood vessels are recognized as an important target for cancer therapy. Tumour endothelial cells (TECs) are the main targets of anti-angiogenic therapy. Unlike the traditionally held view, some TECs may be genetically abnormal and might acquire drug resistance. Therefore, we investigated the drug resistance of TECs and the mechanism by which it is acquired. TECs show resistance to paclitaxel through greater mRNA expression of multidrug resistance 1, which encodes P-glycoprotein, as compared with normal endothelial cells. We found that high levels of vascular endothelial growth factor in tumour-conditioned medium may be responsible for upregulated P-glycoprotein expression. This is a novel mechanism for the acquisition of drug resistance by TECs in a tumour microenvironment. This review focuses on the possibility that TECs can acquire drug resistance.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available